The First Case of an HIV Patient Diagnosed with COVID-19 in Korea

J Korean Med Sci. 2020 Oct 12;35(39):e358. doi: 10.3346/jkms.2020.35.e358.

Abstract

Although some comorbidities, such as diabetes mellitus, lung disease, and chronic kidney disease, are known as risk factors for poor clinical outcome in patients with coronavirus disease 2019 (COVID-19), it is unknown if human immunodeficiency virus (HIV) patients with COVID-19 would have poor prognosis than others. Rare cases of HIV patients with COVID-19 have been reported. As of May 25th, 2020, over 11,000 patients have been diagnosed with COVID-19 and over 13,000 are living with HIV in Korea. Here, we present the first HIV patient with COVID-19 in Korea. The 29-year-old Korean man had been taking Genvoya® regularly for seven years and HIV was well suppressed with CD4 counts of 555/mm³. He had mild symptoms of sore throat, dry cough, loss of taste and smell. He received hydroxychloroquine while Genvoya® was continued. Pneumonia diagnosed in chest computed tomography improved without oxygen supplementation. He was discharged on hospital day 31. HIV patients are considered as immunocompromised, but this case suggests that well controlled HIV patients have satisfactory prognosis following proper medical care.

Keywords: COVID-19; HIV; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Betacoronavirus / genetics
  • Betacoronavirus / isolation & purification
  • CD4 Lymphocyte Count
  • COVID-19
  • Coronavirus Infections / complications
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / virology
  • HIV Infections / complications
  • HIV Infections / pathology*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Male
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / virology
  • Prognosis
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Real-Time Polymerase Chain Reaction
  • SARS-CoV-2
  • Tomography, X-Ray Computed

Substances

  • RNA, Viral
  • Hydroxychloroquine